Efficient Amino Donor Recycling in Amination Reactions: Development of a New Alanine Dehydrogenase in Continuous Flow and Dialysis Membrane Reactors

Transaminases have arisen as one of the main biocatalysts for amine production but despite their many advantages, their stability is still a concern for widespread application. One of the reasons for their instability is the need to use an excess of the amino donor when trying to synthesise amines with unfavourable equilibria. To circumvent this, recycling systems for the amino donor, such as amino acid dehydrogenases or aldolases, have proved useful to push the equilibria while avoiding high amino donor concentrations. In this work, we report the use of a new alanine dehydrogenase from the halotolerant bacteria Halomonas elongata which exhibits excellent stability to different cosolvents, combined with the well characterised CbFDH as a recycling system of L-alanine for the amination of three model substrates with unfavourable equilibria. In a step forward, the amino donor recycling system has been co-immobilised and used in flow with success as well as re-used as a dialysis enclosed system for the amination of an aromatic aldehyde

Diagnostic, prognostic and treatment response of perilipin1 gene in breast cancer

Background: Genetic alterations in the perilipin (PLIN) family genes (PLIN1 to PLIN5) were infrequent in breast cancer (BC) where enhanced levels of PLIN1, PLIN3-5 were observed in the luminal A and luminal B subgroups, whereas increased PLIN2 expression was observed in the HER2-enriched and basal-like subgroups. However, the predictive value of PLIN1 for BC patient outcomes remains uncertain. In the present study, we aim to investigate the diagnostic, prognostic and treatment response roles of the PLIN1 gene expression in BC. Methods: We obtained microarray BC trancriptomic data of 320 tumor (T) and 62 normal (N) breast samples from five GEO data-series; GSE7904 (38 T:7N), GSE42568 (101 T: 15 N), GSE26910 (6 T:6N), GSE45827 (144 T:7N), and GSE10810 (31 T:27 N). The Welch t test was used to analyze the significant differences in gene expression including PLIN1 with fold change > ±2 and p-value 1) and log-rank p-values < 0.05. We also assessed the treatment outcomes of endocrine therapy (tamoxifen and aromatase-inhibitors), anti-HER2 therapy (trastuzumab and lapatinib), and chemotherapy (taxane, anthracycline, and ixabepilone) using robust statistical methods and correlated with PLIN1 gene expression. Results: We identified significantly reduced expression of PLIN1 (FC = −30.76, p value = 2.183e−24) in BC samples compared with normal controls. Our qPCR result confirmed the microarray expression pattern of PLIN1 in BC. Survival analysis revealed PLIN1 to be a moderately important prognostic biomarker. Our findings highlight the effectiveness of trastuzumab and anthracycline in classifying treatment responses, supported by Mann-Whitney tests indicating statistical significance in gene expression differences between responders and non-responders. Conclusion: In conclusion, our findings indicate that PLIN1 is one of the most down-regulated genes and a moderately important biomarker in BC for prognostic purposes. PLIN1 was a good indicator of trastuzumab and anthracycline treatment responses in BC